I-Linagliptin Parent Nucleus Intermediate CAS 853029-57-9 Purity ≥99.0% Factory

Incazelo emfushane:

Igama: Linagliptin Umzali Nucleus Intermediate

I-CAS: 853029-57-9

Ubumsulwa: ≥99.0%

Ukubukeka: Impushana Emhlophe Kuya Kumphuzi Okhanyayo

I-Linagliptin emaphakathi (CAS: 668270-12-0) yokwelashwa kohlobo II lwesifo sikashukela i-mellitus

Ikhwalithi Ephezulu, Ukukhiqizwa Kwezohwebo

E-Mail: alvin@ruifuchem.com


Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

Chemical Properties:

Igama Lekhemikhali 8-Bromo-7-kodwa-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
Omqondofana I-Linagliptin Nucleus yomzali;I-Linagliptin Intermediate F
Inombolo ye-CAS 853029-57-9
Inombolo yeCAT I-RF-PI502
Isimo Sesitoko Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani
I-Molecular Formula I-C20H17BrN6O2
Isisindo samangqamuzana 453.29
Ibhrendi I-Ruifu Chemical

Imininingwane:

Into Imininingwane
Ukubukeka Impushana Emhlophe Kuya Kumphuzi Okhanyayo
Ukuhlonza I-IR/HPLC
Ubumsulwa ≥99.0%
Amanzi (KF) ≤1.0%
Izinsalela ekushiseni ≤0.50%
Ukungcola Okuphelele ≤1.0%
Izinga Lokuhlola I-Enterprise Standard
Ukusetshenziswa Okumaphakathi kwe-Linagliptin (CAS: 668270-12-0)

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwezidingo zekhasimende.

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama.

Izinzuzo:

1

I-FAQ:

Isicelo:

I-8-Bromo-7-kodwa-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (CAS: 853029-57- 9) iyi-nucleus yomzali ye-Linagliptin (CAS: 668270-12-0).I-Linagliptin (amagama ohwebo i-Tradjenta ne-Trajetna) iyisivimbeli se-dipeptidyl peptidase-4 (DPP-4) esagunyazwa yi-US FDA ngoMeyi 2011 ukuze kwelashwe isifo sikashukela soHlobo 2 kanye nokudla nokuzivocavoca.I-Linagliptin (BI-1356) ichazwe njengezinga elinamandla lokukhetha, elihamba kancane kanye ne-inhibitor esebenza isikhathi eside ye-DPP-4.I-Linagliptin iqhamuke emizamweni yokuthuthukisa ye-xanthine-based DPP-4 inhibitors ngomthofu wokuqala okhonjwe kumkhankaso we-HTS.

Bhala umyalezo wakho lapha futhi usithumelele wona